Passage Bio Q2 net loss narrows 16.67% to $7.82 million

Passage Bio posted a net loss of $7.82 million, narrowing from $9.39 million a year earlier; operating loss improved to $8.27 million.

R&D expense fell 42.51% to $3.34 million; general and administrative costs rose 52.06% to $6.87 million.

Other income dropped 52.48% to $451,000; results included a $1.94 million net gain on lease terminations.

The company is winding down gene-therapy programs, terminated key Catalent and Gemma arrangements, and expects its Remix merger to close in Q4 2026.

Cash and cash equivalents totaled $24.2 million as of June 30, 2026, with management flagging substantial doubt about going-concern status.